Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Autolus Therapeutics (AUTL) EBIT: 2017-2025

Historic EBIT for Autolus Therapeutics (AUTL) over the last 6 years, with Sep 2025 value amounting to -$71.6 million.

  • Autolus Therapeutics' EBIT fell 5.52% to -$71.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$273.9 million, marking a year-over-year decrease of 25.18%. This contributed to the annual value of -$241.4 million for FY2024, which is 34.35% down from last year.
  • According to the latest figures from Q3 2025, Autolus Therapeutics' EBIT is -$71.6 million, which was down 17.00% from -$61.2 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' EBIT ranged from a high of -$11.7 million in Q4 2022 and a low of -$39.4 billion during Q3 2021.
  • In the last 3 years, Autolus Therapeutics' EBIT had a median value of -$58.9 million in 2024 and averaged -$56.3 million.
  • Its EBIT has fluctuated over the past 5 years, first crashed by 87,053.61% in 2021, then surged by 99.91% in 2022.
  • Over the past 5 years, Autolus Therapeutics' EBIT (Quarterly) stood at -$23.0 million in 2021, then soared by 49.43% to -$11.7 million in 2022, then crashed by 357.26% to -$53.3 million in 2023, then plummeted by 42.41% to -$75.9 million in 2024, then declined by 5.52% to -$71.6 million in 2025.
  • Its EBIT stands at -$71.6 million for Q3 2025, versus -$61.2 million for Q2 2025 and -$65.2 million for Q1 2025.